Vemurafenib for hard-to-treat BRAF-mutant juvenile histiocytosis
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This Phase 2 study tests the medicine vemurafenib in children with refractory juvenile histiocytosis that has a BRAF mutation. It aims to find a better schedule (timing and dose) for treatment when standard therapies haven’t worked or the disease has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor tissue and/or blood test (circulating tumor DNA) shows a BRAF gene mutation
- Your disease has not responded to standard treatment or has come back after treatment, including specific prior-treatment situations
- You can join the related HISTIOGEN study and sign consent for this trial too
- If you can get pregnant or cause pregnancy, you must use effective birth control during treatment and for at least 1 year after stopping
- You cannot be pregnant or breastfeeding at enrollment
- You must not have certain eye problems (like inflammation of the eye or blocked retinal veins) and must not have known allergy to vemurafenib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether trametinib can work in children or teens with a tumor that does not have BRAF mutations. It also studies the best timing and dose, especially after prior treatments have not worked or the disease came back.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
This study tests an experimental medicine called tovorafenib for children and young adults (6 months to 25 years) with Japanese ancestry whose low-grade brain tumors have returned or grown after prior treatment. The medicine targets tumors with a specific BRAF genetic change.
Hear when a new Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.